

AGC Contracted by Novavax to Manufacture Adjuvant for COVID-19 Vaccine Candidate

Tokyo, June 4, 2020– AGC Inc.(AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, has announced that AGC Biologics (Headquarters: US), a CDMO subsidiary of the company, has been contracted by Novavax Inc. (NASDAQ: NVAX) to manufacture Matrix-M™, the adjuvant component of Novavax' COVID-19 vaccine candidate NVX-CoV2373. AGC Biologics will optimize process development for scaled-up production of Matrix-M™ to significantly increase Novavax' capacity to deliver doses in 2020 and 2021.

Novavax is a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases. NVX-CoV2373 is made using Novavax proprietary nanoparticle technology, with Phase 1 clinical trial results expected in July of 2020, and receiving funding from CEPI (Coalition for Epidemic Preparedness Innovations). Matrix-M™ is Novavax' proprietary adjuvant that is incorporated into the vaccine candidate, in order to enhance the immune response and stimulate high levels of neutralizing antibodies.

AGC Biologics has manufacturing sites in Japan, the US, and Europe, from which it provides a wide variety of high value-added services that range from process development to upscaling, clinical trials, and commercial drug manufacturing. The company has been selected as a manufacturing partner for Matrix-M™, an important component of the COVID-19 vaccine candidate, in recognition of the company's high level of collaboration and commitment.

The AGC Group is committed to helping prevent the spread of COVID-19 and end this pandemic by playing its role in the manufacture of COVID-19 vaccines and drugs for pharmaceutical companies.

REFERENCE

■ About Novavax

Novavax is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Matrix-M™ is Novavax' proprietary saponin-based adjuvant incorporated in the vaccines developed by the company to enhance the immune response and stimulate high levels of neutralizing antibodies.

Visit the URL below for more details.

URL: <http://www.novavax.com>.

MEDIA INQUIRIES

Kazumi Tamaki, General Manager, Corporate Communications & Investor Relations Division
AGC Inc.

(Contact: Yuki Kitano; Tel: +81-3-3218-5603; E-mail: info-pr@agc.com)

*Handling of personal information is governed by our privacy policy.